RATIONAL COMBINATION ANTIHYPERTENSIVE THERAPY WITH BISOPROLOL AND AMLODIPINE


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The current guidelines for the management of arterial hypertension (AH) underline that combination therapy is essential to achieving the proper effect in the majority of patients. Bisoprolol and amlodipine are widely used to treat AH. Bisoprolol is a /З-adrenoblocker that is more commonly used in young patients with vasospastic hypertension accompanied by higher renin levels while amlodipine, a calcium channel blocker, is given to elderly patients with volume-dependent hypertension and low renin activity. Thus, the physiological and pharmacological properties of these drugs determine the rationality of their combination; bisoprolol and amplodipine are characterized by a complementary mechanism of action and are able to minimize the side effects of each other. In addition, the combination therapy makes it possible to increase patient compliance and to ensure effective blood pressure monitoring.

Full Text

Restricted Access

About the authors

F. Babayev

Russian Cardiology Research-and-Production Complex

Email: bosse20077@mail.ru

V. Volkov

Russian Cardiology Research-and-Production Complex

Email: bosse20077@mail.ru

References

  1. Struijker-Boudier H., Ambrosioni E., Holzgreve H. et al. The need for combination antihypertensive therapy to reach target blood pressures: what has been learned from clinical practice and morbidity-mortality trials? // Int. J. Clin. Pract. - 2007; 61: 1592-602.
  2. Mancia G., Grassi G. Management of essential hypertension // Br. Med. Bull. - 2010; 94: 189-99.
  3. Gradman A., Basile J., Carter B. et al. Combination therapy in hypertension // J. Am. Soc. Hypertens. - 2010; 4: 90-8.
  4. Wald D., Law M., Morris J. et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 Trials // Am. J. Med. - 2009; 122: 290-300.
  5. Кобалава Ж.Д., Котовская Ю.В. Место комбинированной терапии с использованием фиксированных комбинаций в лечении артериальной гипертонии // Рац. фармакотер. в кардиологии. - 2010; 6: 550-7.
  6. Sica D. Rationale forfixed-dose combinations in the treatment of hypertension: the cycle repeats // Drugs. - 2002; 62: 443-62.
  7. Willenheimer R. Improving hypertension management: the case for combination therapy // Prim. Care Cardiovasc. J. - 2012; 5: 2.
  8. Hess G. Medication utilization patterns and hypertension-related expenditures among patients who were switched from fixed-dose to free-combination antihypertensive therapy // Pharm. Ther. - 2008; 33: 2121-58.
  9. Bangalore S., Kamalakkannan G., Parkar S. et al. Fixeddose combinations improve medication compliance: a meta-analysis // Am. J. Med. - 2007; 120: 713-9.
  10. Mancia G., de Backer G., Dominiczak A. et al. 2007 Guidelines for the anagement of arterial hypertension //J. Hypertens. - 2007; 25: 1105-87.
  11. Mancia G., Laurent S., Agabiti-Rosei E. et al. Reappraisal of European uidelines on hypertension management: a European Society of ypertension Task Force document // J. Hypertens. - 2009; 27: 2121-58.
  12. Кириченко А.А. Место бисопролола в терапии артериальной гипертензии и ишемической болезни сердца // Фарматека. - 2009; 8: 10-7.
  13. Gillman M., Kannel W., Belanger A. et al. Influence of heart rate on mortality among persons with hypertension: the Framingham Study // Am. Heart J. - 1993; 125: 1148-54.
  14. Palatini P. Role of Elevated Heart Rate in the Development of Cardiovascular Disease in Hypertension // Hypertension. - 2011; 58: 745-50.
  15. Palatini P., Benetos A., Grassi G. et al. Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting // J. Hypertens. - 2006; 24: 603-10.
  16. ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic // JAMA. - 2002; 288: 2981-97.
  17. Dahlof B., Sever P., Wedel H. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial // Lancet. - 2005; 366: 895-906.
  18. Gupta A., Arshad S., Poulter N. Compliance, safety and effectiveness of fixed-dose combinations of antihypertensive drugs: a meta-analysis // Hypertension. - 2010; 55: 399-407.
  19. Rana R., Patil A. Efficacy and safety of bisoprolol plus amlodipine fixed dose combination in essential hypertension // Ind. Pract. - 2008; 61: 225-34.
  20. Mehta S., Shah M., Shah A. et al. Efficacy and tolerability of a fixed dose combination of amlodipine and bisoprolol in essential hypertension // Ind. Pract. - 2005; 58: 751-9.
  21. Law M., Wald N., Morris J. et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials // BMJ. -2003; 326: 1427.
  22. Willenheimer R. The role of beta-blockers and calcium channel blockers in the management of hypertension: Are they all the same? // Hypertens. Rev. - 2011; 2: 18.
  23. Struijker-Boudier H. Role of fixed-dose combinations in improved blood pressure control // Prim. Care Cardiovasc. J. - 2012; 5: 8-12.
  24. http://www.ogyi.hu/kiseroirat/ph/ph_0000033379.pdf

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies